Journal article
Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
AM Scott, PL Mitchell, G O'Keefe, T Saunder, RJ Hicks, A Poon, C Baum, N Brega, TJ McCarthy, GC Toner
Ejnmmi Research | Published : 2012
Abstract
Background We evaluated pharmacodynamic changes in tumour perfusion using positron emission tomography (PET) imaging with 15O-water to assess biological response to sunitinib, a multitargeted tyrosine kinase inhibitor. Methods Patients with advanced malignancies received sunitinib 50 mg/day orally, once daily for 4 weeks on treatment, followed by 2 weeks off treatment, in repeated 6-week cycles. Quantitative measurement of tumour perfusion was assessed using 15O-water-PET at baseline and after 2 weeks of treatment. At least one reference tumour lesion was included in the fields of view and assessed at both time points. Patients also underwent 18F-fluorodeoxyglucose (FDG)-PET imaging at basel..
View full abstractGrants
Funding Acknowledgements
We would like to thank all of the participating patients and their families as well as the investigators, research nurses, study coordinators, and operations staff. This study was sponsored by Pfizer Inc. Editorial support was provided by Nicola Crofts at ACUMED (R) (Tytherington, UK) and was funded by Pfizer Inc.